On May 20th, 2023, transportation of EPICO´s modular pharmaceutical facility project from Pharmadule workshop to port commenced.
Egyptian pharmaceutical company EIPICO´s, EIPICO-3 project is located outside Cairo in 10th of Ramadan City, Egypt. The modular facility part of the project consists of 88 modules and is approximately 5000 sqm.
After completion of the project, the EIPICO-3 facility will be the largest and first factory in Egypt and the Middle East to produce biologicals and biosimilars alternatives and medicine. EIPICO-3 will manufacture biological products, monoclonal antibodies (MABs) and biopharmaceutical proteins.
Pharmadule Morimatsu will have provided conceptual, basic and detailed design as well as fabrication, on-site installation and commissioning & validation. With its strength in design and engineering together with an extensive supply chain and large fabrication facilities Pharmadule Morimatsu offers a one-stop service for modular pharmaceutical facilities.
During the project execution Pharmadule Morimatsu maintained an efficient and close communication with the client team, Egyptian officials, Professional Engineers, and other project stakeholders identifying and solving challenges occurring in the project. As fabrication of the modular facility is done off-site, 88 modules could be fabricated in Pharmadule Morimatsu workshops in 100 days. This includes completing the installation of cleanroom workshop, process equipment, piping, ventilation, electrical systems as well as BMS & EMS, fire alarm and security systems. Thereby reducing the on-site workload and shortening the overall construction period and project program.
Pharmadule Morimatsu has a long experience from delivering modular facilities all over the world. The project managers, design teams and validation experts have in-depth knowledge of industry regulations, codes and product technology. Drivers are the customer needs, innovation and providing the industry with one-stop solution for facility, equipment, and value-added services.
The advantage of the modular solution is that we decrease “time to market”, which ultimately benefits the patients in the Middle East as well as the rest of the world.
About Morimatsu Life Science
Morimatsu Life Science is the sanitary business segment of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), covering industries such as pharmaceuticals, biopharmaceuticals, FMCG, cosmetic and electronic chemicals, and mainly includes Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) Life Technology Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Shanghai Senzhong Biotechnology Co., Ltd., Pharmadule Morimatsu AB (Sweden) and other companies and their affiliates, focusing on the R&D, manufacturing and sales of products in related fields.
Morimatsu, founded in Japan and taken root in China, has developed into a multi-national company that embraces globalization, masters core technology, and gains rich experience from project implementation in diverse fields including core equipment, process systems, and engineering solutions. Starting from its advanced manufacturing base in China, Morimatsu International has opened subsidiaries or plants in Sweden, the United States, India, Italy, Malaysia and Singapore, and has delivered different forms of products and services to more than 40 countries and regions so far, by virtue of its global footprint of efficient and professional team.
The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of “predicted”, “believed”, “forecast”, “planned” and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our Company undertakes no obligation to constantly revise such predicted statements.
Forward-looking statements are based on our Company management’s current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guaranties of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our Company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.